Drug Search Results
More Filters [+]


Alternative Names: rigosertib, ON-01910, ON01910, ON 01910
Latest Update: 2024-05-09
Latest Update Note: Clinical Trial Update

Product Description

SyB L-1101 / SyB C-1101(Generic Name: Rigosertib) is a novel tumor specific PI-3K (phosphoinositide-3 kinase) and PLK (polo-like kinase) inhibitor targeting the Ras Binding Domain being developed by Onconova Therapeutics ("Onconova") for the treatment of hematologic malignancies and solid tumors. Late-stage clinical trials are currently being conducted in the U.S., Europe and India. In addition to the intravenous (IV) formulation in Phase III development (ONTIME) under Special Protocol Assessment (SPA) and orphan drug designation by U.S. FDA for post-hypomethylating agent (HMA) higher-risk myelodysplastic syndromes (HR-MDS), an oral formulation of rigosertib is in Phase II/III development (ONTARGET) for first-line lower-risk MDS (LR-MDS). (Sourced from: https://www.symbiopharma.com/pipeline_e/03.html)

Mechanisms of Action: PI3K Inhibitor,PLK1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Czech

Approved Indications: None

Known Adverse Events: None

Company: Onconova
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rigosertib

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Adenocarcinoma|Non-Small-Cell Lung Cancer



Trial Status


Primary Completion Date

Probability of Success

GCO 19-2243



Adenocarcinoma|Non-Small-Cell Lung Cancer


Recent News Events